

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قال الله تعالى

تَبَارَكَ اسْمُ رَبِّكَ ذِي الْحَلَالِ وَالْإِكْرَامِ

صدق الله العظيم

سورة الرحمن الآية 78

**Dedication:**

To the tutor of this nation the meaning of patience and sacrifices , to whom he devoted his life for the sake of whole humanity ; our prophet blessing and peace of God be upon him .

To my kind mother and my family who always keep their fingers cross to me , to my kith and kin , and to all of my pals .

## **Acknowledgement:**

The gratification in the first instance to the almighty God, Then my massive gratitude to my supervisor Dr. Sana Eltahir for her close guidance and valuable orientation until I finished this piece of research.

My thanks also extend to Dr. Imtisal Elsalamaby ; consultant rheumatologist for

her support and permission for samples collection from her clinic in modern medical center and academy hospital. Also I indebted to the Khartoum teaching hospital staff and Ribat national hospital places where samples were analyzed.

## **List of Abbreviations:**

|              |  |
|--------------|--|
| Anti-CCP     | anti- <a href="#">cyclic citrullinated peptide</a> |
| <u>ACPAs</u> | anti -citrullinated protein antibodies             |
| Anti-MCV     | antibodies against mutated citrullinated Vimentin  |
| ANA          | <u>antinuclear antibody</u>                        |
| ACR          | American College of Rheumatology                   |
| CBC          | complete blood count                               |
| <u>CRP</u>   | c-reactive protein                                 |
| 2,3-DPG      | 2,3-diphosphoglycerate                             |
| EPO          | erythropoietin                                     |
| EBV          | <a href="#">Epstein-Barr virus</a>                 |
| EULAR        | European League Against Rheumatism                 |
| ESR          | <a href="#">erythrocyte sedimentation rate</a>     |
| HHV-6        | <a href="#">Human Herpes Virus 6</a>               |
| MCH          | Mean Corpuscular Hemoglobin                        |
| MCHC         | Mean Corpuscular Hemoglobin Concentration          |
| MCV          | Mean Corpuscular Volume                            |
| MHC          | <a href="#">Major histocompatibility complex</a>   |
| MRI          | magnetic resonance imaging                         |
| RA           | Rheumatoid arthritis                               |
| RBC          | Red blood cell                                     |
| RF           | Rheumatoid Factor                                  |
| TNF          | Tumor Necrosis Factor                              |
| TIBC         | Total iron binding capacity                        |

## **Abstract :**

This is a descriptive cross sectional study which was carried out to determine some immunological parameters (anti-cyclic citrullinated peptide anti-ccp and rheumatoid factor RF ) and some hematological parameters ( complete blood count and erythrocyte sedimentation rate ) in patients with rheumatoid arthritis in Khartoum teaching hospital in the period from January to May 2011.

For this study the total of ninety four rheumatoid arthritis patient samples ( n=94 ) have been used in this study , and ninety four samples (n=94 ) from normal control individuals were tested for anti-cyclic citrullinated peptides by ELISA, rheumatoid factor , complete blood count by Sysmex and erythrocyte sedimentation rate which can be divided as follows : fifty samples were tested for anti-ccp alongside with their fifty normal control individuals and forty four RA samples were tested for ESR ,CBC and RF along with their normal control individuals. The results showed that all the patients with rheumatoid arthritis ( 100% ) were positive for anti-cyclic citrullinated peptides compared to normal control individuals, And forty two rheumatoid arthritis patients were positive for rheumatoid factor latex test and two were negative. Also in the present study the results of forty four patients of rheumatoid arthritis show a slight decrease in the hemoglobin concentration mean Hb (12.1 g/dl  $\pm$ 1.5 SD), red blood cells count mean RBCs ( $4.5 \times 10^{12}/L \pm 0.4$ SD) and packed cell volume mean PCV (37.9%  $\pm$ 4.0 SD) compared to normal control individuals and there were ten patients had their hemoglobin

below the normal range or anemic mean Hb ( 10.1g/dl),and some with lymphopenia mean lymphocyte count (22.7%) as one of the extra-articular complication of rheumatoid arthritis and the erythrocyte sedimentation rate was markedly (P.value=0.00) elevated mean ESR (57.4 mm/ 1hr  $\pm$  34.8 SD) in RA. Also female (76.59 %) were found to be predominantly more affected than male (23.15%) .

## المستخلص:

اجريت هذه الدراسه المقطعيه الوصفية في مستشفى الخرطوم التعليمي في الفتره من يناير الي مايو 2011 لتحديد بعض القياسات المناعيه ( قياس الجسم المضاد للسترولين وعامل الروماتيزم ) وتحديد بعض القياسات الدموية ( حساب جميع خلايا الدم والترسيب ) للمصابين بالروماتيزم .

ولهذا الغرض جمعت اربع وتسعون عينة من اشخاص مصابين بالروماتيزم وتم تحليلها جنبا الي جنب مع اربع وتسعون عينة تم اخذها من اشخاص اصحاء من اجل مقارنتها مع عينات المرضي وتم تقسيمها كالتالي:

تم قياس الجسم المضاد للسترولين لخمسين من المرضي وخمسين من عينات الاصحاء وتم قياس عامل الروماتيزم ، الترسيب وحساب جميع خلايا الدم لاربعة واربعون من المرضي واربعون من عينات الاصحاء. وقد خلصت الدراسه الى ان جميع الاشخاص المصابون بالروماتيزم ايجابيين للجسم المضاد للسترولين بنسبة(100%) مقارنة بالاشخاص الاصحاء الذين جميعهم سلبيين للجسم المضاد للسترولين ، وان اثنين واربعون من المرضي ايجابيين لعامل الروماتيزم واثنين سلبيين من جملة اربعة واربعون مريضا وان بعض المرضي لديهم نقص في الخلايا الليمفية متوسط عدد الخلايا الليمفية يساوي ( 22.7 في المائه ) ، وان عشرة منهم لديهم نقص في خضاب الدم المتوسط يساوي ( 10.1 جرام للديسيليتر ) دون الحد الطبيعي اي مصابون بفقر الدم نتيجة للروماتيزم المزمن ، وايضا هنالك ارتفاع ملحوظ في الترسيب متوسط الترسيب يساوي ( 57 ملميتري في الساعه ) .

وقد خلصت الدراسه ايضا الي ان الغالبيه العظمي من المصابين بالروماتيزم هم 23.5 ( % ) النساء ( 76.5 % ) دون الرجال .

## **List of contents:**

| Subject               | Page No |
|-----------------------|---------|
| الاًدلة               | I       |
| Dedication            | II      |
| Acknowledgement       | III     |
| List of abbreviations | IV      |
| Abstract( English)    | V       |
| <b>المستخلص</b>       | VI      |
| List of contents      | VII     |
| List of tables        | X       |
| Lists of figures      | XI      |

### **Chapter one Introduction and literature review :**

|           |                                       |    |
|-----------|---------------------------------------|----|
| 1.1       | Introduction:                         | 1  |
| 1.2       | Anti-citrullinated protein antibody : | 4  |
| 1.2.1     | Clinical Use of Anti-CCP:             | 7  |
| 1.3       | Anemia of chronic disease:            | 8  |
| 1.3.1     | Pathophysiology:                      | 8  |
| 1.3.2     | Diagnosis:                            | 10 |
| 1.3.3     | Treatment                             | 11 |
| 1.4       | Rheumatoid arthritis :                | 11 |
| 1.4.1     | Clinical features :                   | 12 |
| 1.4.1.1   | Hematological changes :               | 13 |
| 1.4.2 .   | Pathophysiology :                     | 13 |
| 1.4.3     | Causes and associated factors :       | 15 |
| 1.4.3.1   | Possible infectious triggers :        | 15 |
| 1.4.3.2   | Psychological factors :               | 16 |
| 1.4.3.3 . | Continued abnormal immune response :  | 16 |
| 1.4.4     | Diagnosis :                           | 17 |

|          |                                  |    |
|----------|----------------------------------|----|
| 1.4.4.1  | Blood tests :                    | 17 |
| 1.4.4.2. | Imaging :                        | 18 |
| 1.4.4.3  | Rheumatoid factor :              | 19 |
| 1.4.4.4  | Erythrocyte sedimentation rate : | 19 |
| 1.4.5    | Criteria :                       | 19 |
| 1.4.6    | Epidemiology :                   | 20 |
| 1.5.1    | Objectives :                     | 22 |
| 1.5.1.1  | General objective :              | 22 |
| 1.5.1.2  | Specific objectives :            | 22 |
| 1. 5.2   | Rationale:                       | 23 |

**Chapter two**  
**Materials and methods :**

|             |                             |    |
|-------------|-----------------------------|----|
| 2.1.1       | Study population :          | 24 |
| 2.1.2       | Study design :              | 24 |
| 2.1.3       | Sampling :                  | 24 |
| 2.1.4       | Materials :                 | 24 |
| 2.1.5       | Methods :                   | 25 |
| 2.1.5.1     | Anti-ccp ELISA :            | 25 |
| 2.1.5.1.1   | Principle of the test :     | 25 |
| 2.1.5.1.2.  | Performance of the test :   | 25 |
| 2.1.5.1.3   | Calculation of results :    | 26 |
| 2.1.5.1.4 . | Interpretation of results : | 26 |
| 3.1.5.2     | Complete blood count :      | 26 |

**Chapter Three**  
**Results :**

|     |           |    |
|-----|-----------|----|
| 3.1 | Results : | 28 |
|-----|-----------|----|

**Chapter Four**

|                  |    |
|------------------|----|
| Discussion :     | 36 |
| Conclusion:      | 38 |
| Recommendations: | 39 |
| References       | 40 |
| Appendix( 1)     | 41 |
| Appendix( 2)     | 42 |

## **List of tables:**

| Table No  | Title  | PageNo |
|-----------|--|--------|
| Table( 1) | Comparison between the means of red cells indices in tests and controls.                       | 28     |
| Table( 2) | Comparison between the means of WBCs, differential count , plts and ESR in tests and controls. | 29     |
| Table( 3) | Comparison between the rheumatoid factor results of the tests and controls.                    | 30     |
| Table( 4) | Comparison between RF according to the gender .  | 31     |
| Table( 5) | Frequency of positive and negative anti-ccp in study population.                               | 32     |
| Table( 6) | Comparison between patients with positive anti.ccp and control individuals.                    | 33     |
| Table (7) | Comparison between patients anti-ccp and controls among gender .                               | 34     |

## **List of figures:**

| Figure No  | Title   | PageN o |
|------------|---|---------|
| Figure (1) | Citrulline  | 4       |
| Figure (2) | The enzymatic conversion of arginine to citrulline                          | 6       |
| Figure (3) | Comparison between patients with positive anti CCP and control individuals. | 30      |
| Figure (4) | Comparison between RF according to the gender .                             | 31      |
| Figure (5) | Frequency of positive and negative anti CCP in study population.            | 32      |
| Figure (6) | Comparison between patients with positive anti CCP and control individuals. | 33      |
| Figure (7) | Comparison between patients anti CCP among gender .                         | 34      |
| Figure (8) | Comparison between controls anti CCP among gender .                         | 35      |